CMS Open Payments · Program Year 2024
Mannkind Corporation
Mannkind Corporation reported $3,661,643.19 across General Payments, Research, and Ownership to 10,087 physicians and teaching hospitals across 16,709 transactions.
- $3.7M Top quartile payer
- All-tracks total
- 16,709 Top 10% volume
- Transactions
- 10,087 Top quartile reach
- Recipients
- −$426.0K
- General Payments vs PY2023
Mannkind Corporation reported $3,661,643.19 across all CMS Open Payments tracks (General + Research + Ownership) to 10,087 physicians and teaching hospitals in Program Year 2024 - ranking #322 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $423,228.14, averaging $363.01 per recipient.
How Mannkind Corporation's $3.7M all-tracks total breaks down
Mannkind Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
77/100
Total payments
F
44/100
Transaction volume
A
100/100
Physician reach
B
87/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mannkind-corporation Mannkind Corporation
$3.7M · #322/1,925 · 0.0% industry · PY2024
- TOT $3.7M
- RANK #322
- SHARE 0.0%
- TXN 16,709
- RCP 10,087
- CAT 6
- GEN $423.2K
- ΔGEN −$426.0K
- TOP1 7.4%
- PY 2024
Volume peers
Nearest volume peer: Gramercy Extremity Orthopedics LLC ($3.7M)
Mannkind Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Mannkind Corporation's CMS-reported General Payments decreased by $426.0K (−50.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MANNKIND CORPORATIONPY2023: MANNKIND CORPORATIONPY2024: Mannkind Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $849,222.38
- PY2024
- $423,228.14
What the Data Shows for Mannkind Corporation
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Mannkind Corporation, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Food and Beverage" leads the 6-category general-payment breakdown below at $182.5K (43.1% of General Payments, 9,732 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Food and Beverage" leads Mannkind Corporation's 6-category general-payment breakdown at $182.5K, 43.1% of the reported total.
Mannkind Corporation reports 6 general-payment categories - the top three are Food and Beverage (43.1%), Compensation for Services Other Than Consulting (40.7%), and Travel and Lodging (12.6%). The remaining 3 categories make up 3.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Mannkind Corporation divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $182.5K | 9,732 | 43.1% |
| Compensation for Services Other Than Consulting | $172.2K | 119 | 40.7% |
| Travel and Lodging | $53.1K | 172 | 12.6% |
| Consulting Fee | $13.3K | 3 | 3.1% |
| Gift | $2.0K | 46 | 0.5% |
| Education | $210.00 | 15 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $77,373.84 (18.3%) of $423,228.14 in this company's General Payments records across 2,583 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Mannkind Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Brandy R Biederman
$31,307.85 across 93 reported transactions
- 2
Perry B Herson
$12,882.61 across 41 reported transactions
- 3
Theofanis Mitsinikos
$11,400.10 across 32 reported transactions
- 4
Misha Denham
$11,208.63 across 19 reported transactions
- 5
Martin Sarkar
$10,574.65 across 32 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Mannkind Corporation ranks #322 of 1,925 by total payments (top 17% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,633 of 1,838 by HHI (bottom 11% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Aimmune Therapeutics, Inc. : $2.1M total payments, HHI 149
- Insmed, Inc. : $1.1M total payments, HHI 148
- Ermi LLC : $10.5K total payments, HHI 145
- Vertos Medical, Inc. : $796.2K total payments, HHI 142
- Thrombolex, Inc. : $11.1K total payments, HHI 142
- Scpharmaceuticals Inc. : $980.4K total payments, HHI 141
- Mannkind Corporation (this company) : $423.2K total payments, HHI 141
- Hill Dermaceuticals, Inc. : $15.7K total payments, HHI 140
- Axogen : $1.8M total payments, HHI 139
- Johnson and Johnson International : $11.1K total payments, HHI 138
- Alon Medical Technology : $48.8K total payments, HHI 138
- Insulet Corporation : $3.9M total payments, HHI 137
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Mannkind Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Mannkind Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Mannkind Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Merz North America, Inc.
Adcura, Inc.
Paragon 28, Inc.
Axonics, Inc.
Haemonetics Corporation
Put this to use
Mannkind Corporation ranks #322 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Mannkind Corporation sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Mannkind Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.